Ten-year follow-up shows efficacy of Sanofi's MS drug Lemtrada

19 April 2016

New data from a 10-year follow-up study showing the effectiveness of Lemtrada (alemtuzumab) in patients with relapsing-remitting multiple sclerosis (MS) has been presented by French pharma major Sanofi (Euronext: SAN).

The company’s specialty care global business unit, Sanofi Genzyme, presented results from the ongoing, long-term extension study of the Phase II CAMMS223 trial at the 68th American Academy of Neurology (AAN) 2016 Annual Meeting in Vancouver, Canada.

Results showed that 76% of patients were free from six-month confirmed disability worsening and 78% had an expanded disability status scale (EDSS) score that was either stable or showed greater than or equal to a one point improvement in EDSS against the baseline figure. In addition, a low annualized relapse rate was maintained over the period.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology